Literature DB >> 23932070

Medicinal attributes of pyrazolo[3,4-d]pyrimidines: a review.

Monika Chauhan1, Raj Kumar.   

Abstract

Pyrazolopyrimidines are the fused heterocyclic ring systems which structurally resemble purines which prompted biological investigations to assess their potential therapeutic significance. They are known to play a crucial role in numerous disease conditions. The advent of their first bioactivity as adenosine antagonistic property divulged their medicinal potential. Radioactivity test on mice cells, morphometric and serological tests on rat hepatocytes, antitumor testing against L1210 and P388 leukemias in mice threw light on their biophysical aspects of significance. Biochemical properties were explored via xanthine oxidase assay, antioxidant enzyme assays, Western blot analysis, mRNA expression of apoptopic genes, receptor binding assays, and tryptan blue exclusion cytotoxicity evaluation. The collective results of biochemical and biophysical properties foregrounded their medicinal significance in central nervous system, cardiovascular system, cancer, inflammation etc. The present manuscript to the best of our knowledge is the first compilation on synthesis and medicinal aspects including structure-activity relationships of pyrazolo[3,4-d]pyrimidines reported to date.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activities; IC(50); Pyrazolo[3,4-d]pyrimidine; SAR

Mesh:

Substances:

Year:  2013        PMID: 23932070     DOI: 10.1016/j.bmc.2013.07.027

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  14 in total

1.  Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors.

Authors:  Nashwa M Saleh; Marwa G El-Gazzar; Hala M Aly; Rana A Othman
Journal:  Front Chem       Date:  2020-01-24       Impact factor: 5.221

Review 2.  Pyrazoles as potential anti-angiogenesis agents: a contemporary overview.

Authors:  Konstantinos M Kasiotis; Evangelia N Tzanetou; Serkos A Haroutounian
Journal:  Front Chem       Date:  2014-09-09       Impact factor: 5.221

3.  Crystal structure of 1-methyl-4-methyl-sulfanyl-1H-pyrazolo-[3,4-d]pyrimidine.

Authors:  Mohammed El Fal; Youssef Ramli; El Mokhtar Essassi; Mohamed Saadi; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-11-21

4.  Synthesis of some novel pyrazolo[3,4-d] pyrimidin-4(5H)-one derivatives as potential antimicrobial agent.

Authors:  Dipen K Sureja; Sandip P Dholakia; Kantilal R Vadalia
Journal:  J Pharm Bioallied Sci       Date:  2016 Oct-Dec

5.  Plasma metabolomic profiling of proliferative diabetic retinopathy.

Authors:  Xiao-Rong Zhu; Fang-Yuan Yang; Jing Lu; Hui-Rong Zhang; Ran Sun; Jian-Bo Zhou; Jin-Kui Yang
Journal:  Nutr Metab (Lond)       Date:  2019-05-28       Impact factor: 4.169

Review 6.  Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold.

Authors:  Daniel J Baillache; Asier Unciti-Broceta
Journal:  RSC Med Chem       Date:  2020-09-08

7.  A convenient four-component one-pot strategy toward the synthesis of pyrazolo[3,4-d]pyrimidines.

Authors:  Mingxing Liu; Jiarong Li; Hongxin Chai; Kai Zhang; Deli Yang; Qi Zhang; Daxin Shi
Journal:  Beilstein J Org Chem       Date:  2015-11-06       Impact factor: 2.883

8.  Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.

Authors:  Mai Maher; Asmaa E Kassab; Ashraf F Zaher; Zeinab Mahmoud
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

9.  Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway.

Authors:  Teresa Valero; Daniel J Baillache; Craig Fraser; Samuel H Myers; Asier Unciti-Broceta
Journal:  Bioorg Med Chem       Date:  2019-11-25       Impact factor: 3.641

10.  Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors.

Authors:  Chiara Greco; Rosa Catania; Dario Leonardo Balacco; Vincenzo Taresco; Francesca Musumeci; Cameron Alexander; Alan Huett; Silvia Schenone
Journal:  Molecules       Date:  2020-11-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.